Droperidol

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Droperidol
Skeletal formula of droperidol
(IUPAC) ime
1-{1-[4-(4-fluorofenil)-4-oksobutil]-1,2,5,6-tetrahidropiridin-4-il}-1,3-dihidro-2H-benzimidazol-2-on
Klinički podaci
Identifikatori
CAS broj 548-73-2
ATC kod N05AD08
PubChem[1][2] 3168
DrugBank DB00450
UNII O9U0F09D5X DaY
KEGG[3] D00308
ChEMBL[4] CHEMBL1108 DaY
Hemijski podaci
Formula C22H22FN3O2 
Mol. masa 379,428 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Metabolizam Hepatički
Poluvreme eliminacije 2,3 sata
Farmakoinformacioni podaci
Trudnoća ?
Pravni status -only (SAD)
Način primene Intravenozno, Intramaskularno

Droperidol (Inapsine, Droleptan, Dridol, Xomolix, Innovar [kombinacija sa fentanilom]) je antidopaminergički lek koji se koristi kao antiemetik i antipsihotik.[5][6] Droperidol se takođe koristi za neuroleptanalgezijsku anesteziju i sedaciju pri intenzivnoj nezi.

Hemija[uredi | uredi kod]

Droperidol se može sintetisati iz 1-benzil-3-karbetoksipiperidin-4-ona, reakcijom sa o-fenilendiaminom.[7][8][9][10]

Reference[uredi | uredi kod]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682. 
  6. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412. 
  7. C. Janssen, NV Res. Lab., GB 989755  (1962).
  8. Janssen, P. A. J.; 1963, Belgian Patent BE 626307 .
  9. F.J. Gardocki, J. Janssen, U.S. Patent 3.141.823 (1964).
  10. P.A.J. Janssen, U.S. Patent 3.161.645 (1964).

Literatura[uredi | uredi kod]

  • Scuderi PE: Droperidol: Many questions, few answers. Anesthesiology 2003; 98: 289-90
  • Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Department of Anesthesiology and Resuscitation, Johann Wolfgang Goethe-University Clinics, Frankfurt am Main, Germany.
  • Emergency Medicine Magazine : http://www.emedmag.com/html/pre/tri/1005.asp Arhivirano 2011-05-27 na Wayback Machine-u

Spoljašnje veze[uredi | uredi kod]